INKT

Mink Therapeutics, Inc.

• TipRanks·5d ago

  MiNK Therapeutics reports new data on agenT-797 at ATS 2026

• Benzinga·5d ago

  MiNK Therapeutics Presents New Clinical, Translational Data On Agent-797 Showing Pathogen Suppression, Lung Immune Restoration And Tissue Repair Activation, Supporting Ongoing Phase 2 Trial, At ATS 2026

• PUBT·5d ago

  Mink Therapeutics starts Phase 2 trial of agenT-797 in severe acute lung injury

• Dow Jones·05/18 15:22

  MiNK Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co.

• Benzinga·05/18 15:12

  HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

• TipRanks·05/18 06:30

  Analysts Are Bullish on These Healthcare Stocks: Biofrontera (BFRI), MiNK Therapeutics (INKT)

• TipRanks·05/16 00:08

  Mink Therapeutics’ Earnings Call: High Promise, Tight Runway

• Seeking Alpha·05/15 20:51

  MiNK outlines 90-patient randomized Phase II ARDS trial with initial data expected in 2H 2026

• Benzinga·05/15 13:46

  Transcript: MiNK Therapeutics Q1 2026 Earnings Conference Call

• Benzinga·05/15 12:06

  12 Health Care Stocks Moving In Friday's Pre-Market Session

• Seeking Alpha·05/15 11:43

  MiNK Therapeutics GAAP EPS of -$0.57 beats by $0.20

• Reuters·05/15 11:39

  MiNK Therapeutics' Q1 net loss narrows slightly

• PUBT·05/15 11:31

  MiNK Therapeutics Q1 FY26 net loss narrows to $2.74 million

• Dow Jones·05/15 11:31

  *MiNK Therapeutics 1Q Loss/Shr 57c >INKT

• Dow Jones·05/15 11:30

  Press Release: MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation